Cargando…

Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation

ALK-negative anaplastic large cell lymphoma is a rare T-cell neoplasm with an aggressive course requiring prompt diagnostic work-up and treatment. Few cases of concomitant multiple myeloma and T-cell neoplasm are described in the literature, mainly regarding primary cutaneous anaplastic large cell l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staderini, Michela, Mannelli, Lara, Antonioli, Elisabetta, Puccini, Benedetta, Berti, Valentina, Mungai, Francesco, Vergoni, Federica, Carrai, Valentina, Rigacci, Luigi, Bosi, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201522/ https://www.ncbi.nlm.nih.gov/pubmed/32509362 http://dx.doi.org/10.1155/2020/6309736

Ejemplares similares

The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas
por: Rigacci, Luigi, et al.
Publicado: (2018)

Patients with ≥ 20 × 10(9)/L Platelets at Baseline May Have a Prompt Response to Romiplostim During the Early Phase of Treatment: an Italian Single-Institution Experience
por: Baldini, Simone, et al.
Publicado: (2012)

Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen
por: Rigacci, Luigi, et al.
Publicado: (2014)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Long non-coding RNA mitophagy and ALK-negative anaplastic lymphoma-associated transcript: a novel regulator of mitophagy in T-cell lymphoma
por: Mularoni, Valentina, et al.
Publicado: (2023)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Mild exposure of RIN-5F β-cells to human islet amyloid polypeptide aggregates upregulates antioxidant enzymes via NADPH oxidase-RAGE: An hormetic stimulus()
por: Borchi, Elisabetta, et al.
Publicado: (2013)

Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques
por: Abenavoli, Elisabetta Maria, et al.
Publicado: (2023)

Pathobiology of ALK-negative anaplastic large cell lymphoma
por: Pileri, Stefano A., et al.
Publicado: (2011)

ALK-positive anaplastic large cell lymphoma in adults
por: Gromowsky, Matthew J, et al.
Publicado: (2023)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

P034: Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment
por: Romano, Ilaria, et al.
Publicado: (2022)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
por: Masood, Ashiq, et al.
Publicado: (2021)

Aggressive Multiple Myeloma with Unusual Morphology
por: Sönmez, Mehmet, et al.
Publicado: (2014)

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
por: Tabbó, Fabrizio, et al.
Publicado: (2012)

Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma
por: Satou, Akira, et al.
Publicado: (2020)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
por: Werner, Michael T., et al.
Publicado: (2017)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Update on Anaplastic Thyroid Carcinoma: Morphological, Molecular, and Genetic Features of the Most Aggressive Thyroid Cancer
por: Ragazzi, Moira, et al.
Publicado: (2014)

Clinical and histopathological analyses of anaplastic myeloma
por: Huang, Jun-Xia, et al.
Publicado: (2020)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma
por: Krishnamurthy, Savitri, et al.
Publicado: (2013)

ALK-positive anaplastic large cell lymphoma that presented as pleural effusion
por: Kim, Do Hwan, et al.
Publicado: (2022)

ALK-Positive Anaplastic Large Cell Lymphoma Associated With Hemophagocytic Lymphohistiocytosis
por: Chao, Shing, et al.
Publicado: (2023)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
por: Antonioli, Elisabetta, et al.
Publicado: (2023)

Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation
por: Buda, Gabriele, et al.
Publicado: (2021)

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
por: Chioureas, Dimitrios, et al.
Publicado: (2022)

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene
por: van der Krogt, Jo-Anne, et al.
Publicado: (2017)

Endobronchial ALK-Positive Anaplastic Large Cell Lymphoma Presenting Massive Hemoptysis
por: Kim, Hee Kyung, et al.
Publicado: (2015)

Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma
por: Fuchs, Steffen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ksgsam7k8o7pr5nt7dumr2dlfq